Details for Patent: 9,737,488
✉ Email this page to a colleague
Which drugs does patent 9,737,488 protect, and when does it expire?
Patent 9,737,488 protects NEXAVAR and is included in one NDA.
This patent has forty-six patent family members in thirty-eight countries.
Summary for Patent: 9,737,488
| Title: | Pharmaceutical composition for the treatment of cancer |
| Abstract: | The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliferative diseases, such as cancer, either as a sole agent, or in combination with other anti-cancer therapies, and the process for preparing of said composition. |
| Inventor(s): | Schuckler; Fritz (Bergisch Gladbach, DE), Wollenschlager; Axel (Bergisch Gladbach, DE) |
| Assignee: | Bayer HealthCare LLC (Whippany, NJ) |
| Application Number: | 11/885,930 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,737,488 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Process; Dosage form; |
Drugs Protected by US Patent 9,737,488
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT | ⤷ Sign Up | ||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF ADVANCED RENAL CELL CARCINOMA | ⤷ Sign Up | ||
| Bayer Hlthcare | NEXAVAR | sorafenib tosylate | TABLET;ORAL | 021923-001 | Dec 20, 2005 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,737,488
| PCT Information | |||
| PCT Filed | February 22, 2006 | PCT Application Number: | PCT/EP2006/001574 |
| PCT Publication Date: | September 14, 2006 | PCT Publication Number: | WO2006/094626 |
International Family Members for US Patent 9,737,488
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 054234 | ⤷ Sign Up | |||
| Austria | E482693 | ⤷ Sign Up | |||
| Australia | 2006222365 | ⤷ Sign Up | |||
| Brazil | PI0608840 | ⤷ Sign Up | |||
| Canada | 2601955 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
